Illumina Total Revenue vs Ebitda Analysis

ILMN Stock

USD 136.99 5.31 4.03%

Illumina financial indicator trend analysis is infinitely more than just investigating Illumina recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Illumina is a good investment. Please check the relationship between Illumina Total Revenue and its Ebitda accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.

Total Revenue vs Ebitda

Total Revenue vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Illumina Total Revenue account and Ebitda. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Illumina's Total Revenue and Ebitda is -0.44. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Ebitda in the same time period over historical financial statements of Illumina, assuming nothing else is changed. The correlation between historical values of Illumina's Total Revenue and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Illumina are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Total Revenue i.e., Illumina's Total Revenue and Ebitda go up and down completely randomly.

Correlation Coefficient

-0.44

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Total Revenue

Total revenue comprises all receipts Illumina generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Ebitda

Most indicators from Illumina's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Illumina current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.At this time, Illumina's Selling General Administrative is very stable compared to the past year. As of the 22nd of November 2024, Enterprise Value is likely to grow to about 1.6 B, while Tax Provision is likely to drop about 41.8 M.

	2021	2022	2023	2024 (projected)
Gross Profit	3.2B	3.0B	2.7B	2.9B
Total Revenue	4.5B	4.6B	4.5B	4.7B

Gross Profit Total Revenue

Illumina fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Other Liab	Current Deferred Revenue
Total Assets		0.92	0.73	0.77	0.98	0.93	0.71	0.51	0.98	0.64	0.96	0.81	0.28	0.91	0.47	-0.21	0.96	0.84	0.8	0.95	0.52	0.35	0.86	0.5	0.93	0.93
Short Long Term Debt Total	0.92		0.8	0.93	0.85	0.91	0.73	0.38	0.93	0.74	0.83	0.78	0.42	0.91	0.58	-0.1	0.9	0.87	0.74	0.98	0.63	0.61	0.79	0.59	0.81	0.93
Other Current Liab	0.73	0.8		0.8	0.63	0.75	0.77	-0.11	0.76	0.37	0.73	0.46	0.03	0.87	0.36	-0.39	0.81	0.9	0.87	0.87	0.25	0.3	0.85	0.36	0.8	0.86
Total Current Liabilities	0.77	0.93	0.8		0.66	0.79	0.74	0.2	0.81	0.63	0.68	0.73	0.39	0.81	0.43	-0.03	0.71	0.83	0.65	0.91	0.58	0.79	0.7	0.45	0.7	0.84
Total Stockholder Equity	0.98	0.85	0.63	0.66		0.9	0.64	0.6	0.95	0.61	0.96	0.79	0.26	0.85	0.41	-0.2	0.94	0.76	0.74	0.88	0.49	0.26	0.81	0.45	0.9	0.87
Property Plant And Equipment Net	0.93	0.91	0.75	0.79	0.9		0.53	0.55	0.93	0.77	0.83	0.73	0.48	0.94	0.44	-0.05	0.9	0.83	0.66	0.92	0.68	0.4	0.72	0.5	0.81	0.96
Net Debt	0.71	0.73	0.77	0.74	0.64	0.53		-0.11	0.72	0.1	0.78	0.59	-0.17	0.65	0.33	-0.41	0.7	0.75	0.88	0.78	0.05	0.41	0.87	0.3	0.79	0.69
Retained Earnings	0.51	0.38	-0.11	0.2	0.6	0.55	-0.11		0.48	0.68	0.36	0.55	0.69	0.36	0.31	0.46	0.37	0.09	-0.09	0.32	0.73	0.23	0.03	0.38	0.26	0.39
Accounts Payable	0.98	0.93	0.76	0.81	0.95	0.93	0.72	0.48		0.64	0.93	0.83	0.3	0.93	0.52	-0.18	0.95	0.83	0.77	0.96	0.54	0.4	0.83	0.55	0.92	0.96
Cash	0.64	0.74	0.37	0.63	0.61	0.77	0.1	0.68	0.64		0.45	0.62	0.77	0.65	0.54	0.28	0.59	0.5	0.19	0.66	0.89	0.53	0.28	0.61	0.39	0.65
Non Current Assets Total	0.96	0.83	0.73	0.68	0.96	0.83	0.78	0.36	0.93	0.45		0.75	0.01	0.82	0.33	-0.45	0.94	0.83	0.89	0.89	0.27	0.22	0.94	0.35	0.95	0.85
Non Currrent Assets Other	0.81	0.78	0.46	0.73	0.79	0.73	0.59	0.55	0.83	0.62	0.75		0.35	0.64	0.44	-0.01	0.71	0.58	0.53	0.78	0.56	0.58	0.61	0.5	0.72	0.71
Cash And Short Term Investments	0.28	0.42	0.03	0.39	0.26	0.48	-0.17	0.69	0.3	0.77	0.01	0.35		0.38	0.51	0.81	0.19	0.08	-0.25	0.3	0.95	0.53	-0.2	0.56	0.02	0.37
Net Receivables	0.91	0.91	0.87	0.81	0.85	0.94	0.65	0.36	0.93	0.65	0.82	0.64	0.38		0.57	-0.11	0.93	0.84	0.75	0.95	0.59	0.33	0.78	0.6	0.86	0.99
Common Stock Shares Outstanding	0.47	0.58	0.36	0.43	0.41	0.44	0.33	0.31	0.52	0.54	0.33	0.44	0.51	0.57		0.28	0.54	0.32	0.26	0.53	0.63	0.27	0.23	0.97	0.38	0.54
Short Term Investments	-0.21	-0.1	-0.39	-0.03	-0.2	-0.05	-0.41	0.46	-0.18	0.28	-0.45	-0.01	0.81	-0.11	0.28		-0.32	-0.42	-0.63	-0.21	0.64	0.34	-0.62	0.31	-0.41	-0.12
Non Current Liabilities Total	0.96	0.9	0.81	0.71	0.94	0.9	0.7	0.37	0.95	0.59	0.94	0.71	0.19	0.93	0.54	-0.32		0.85	0.85	0.94	0.43	0.21	0.88	0.55	0.94	0.93
Other Current Assets	0.84	0.87	0.9	0.83	0.76	0.83	0.75	0.09	0.83	0.5	0.83	0.58	0.08	0.84	0.32	-0.42	0.85		0.87	0.91	0.31	0.39	0.9	0.33	0.84	0.87
Other Stockholder Equity	0.8	0.74	0.87	0.65	0.74	0.66	0.88	-0.09	0.77	0.19	0.89	0.53	-0.25	0.75	0.26	-0.63	0.85	0.87		0.83	0.0	0.13	0.98	0.24	0.9	0.76
Total Liab	0.95	0.98	0.87	0.91	0.88	0.92	0.78	0.32	0.96	0.66	0.89	0.78	0.3	0.95	0.53	-0.21	0.94	0.91	0.83		0.54	0.5	0.86	0.55	0.9	0.96
Total Current Assets	0.52	0.63	0.25	0.58	0.49	0.68	0.05	0.73	0.54	0.89	0.27	0.56	0.95	0.59	0.63	0.64	0.43	0.31	0.0	0.54		0.59	0.07	0.7	0.26	0.58
Short Term Debt	0.35	0.61	0.3	0.79	0.26	0.4	0.41	0.23	0.4	0.53	0.22	0.58	0.53	0.33	0.27	0.34	0.21	0.39	0.13	0.5	0.59		0.2	0.28	0.2	0.38
Intangible Assets	0.86	0.79	0.85	0.7	0.81	0.72	0.87	0.03	0.83	0.28	0.94	0.61	-0.2	0.78	0.23	-0.62	0.88	0.9	0.98	0.86	0.07	0.2		0.23	0.93	0.8
Common Stock	0.5	0.59	0.36	0.45	0.45	0.5	0.3	0.38	0.55	0.61	0.35	0.5	0.56	0.6	0.97	0.31	0.55	0.33	0.24	0.55	0.7	0.28	0.23		0.4	0.57
Other Liab	0.93	0.81	0.8	0.7	0.9	0.81	0.79	0.26	0.92	0.39	0.95	0.72	0.02	0.86	0.38	-0.41	0.94	0.84	0.9	0.9	0.26	0.2	0.93	0.4		0.88
Current Deferred Revenue	0.93	0.93	0.86	0.84	0.87	0.96	0.69	0.39	0.96	0.65	0.85	0.71	0.37	0.99	0.54	-0.12	0.93	0.87	0.76	0.96	0.58	0.38	0.8	0.57	0.88

Click cells to compare fundamentals

Illumina Account Relationship Matchups

Illumina fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.3B	7.6B	15.2B	12.3B	10.1B	10.6B
Short Long Term Debt Total	1.8B	1.9B	2.5B	3.5B	2.3B	2.4B
Other Current Liab	304M	236M	358M	814M	908M	953.4M
Total Current Liabilities	665M	1.2B	1.1B	2.8B	1.6B	1.6B
Total Stockholder Equity	4.6B	4.7B	10.7B	6.6B	5.7B	6.0B
Property Plant And Equipment Net	1.4B	1.5B	1.7B	1.7B	1.6B	1.6B
Net Debt	(206M)	45M	1.2B	1.5B	1.2B	1.3B
Retained Earnings	4.1B	4.7B	5.5B	1.1B	(19M)	(18.1M)
Accounts Payable	149M	192M	332M	293M	245M	257.3M
Cash	2.0B	1.8B	1.2B	2.0B	1.0B	673.0M
Non Current Assets Total	2.9B	3.1B	12.5B	8.7B	7.5B	7.9B
Non Currrent Assets Other	105M	171M	445M	423M	217M	123.4M
Cash And Short Term Investments	3.4B	3.5B	1.3B	2.0B	1.1B	1.2B
Net Receivables	573M	487M	648M	688M	752M	789.6M
Short Term Investments	1.4B	1.7B	107M	26M	6M	5.7M
Liabilities And Stockholders Equity	7.3B	7.6B	15.2B	12.3B	10.1B	10.6B
Non Current Liabilities Total	2.0B	1.6B	3.4B	2.9B	2.8B	2.9B
Other Current Assets	105M	290M	295M	536M	432M	453.6M
Other Stockholder Equity	539M	(33M)	5.2B	5.5B	5.8B	6.1B
Total Liab	2.7B	2.9B	4.5B	5.7B	4.4B	4.6B
Total Current Assets	4.5B	4.5B	2.7B	3.6B	2.6B	1.8B
Short Term Debt	45M	562M	71M	1.3B	86M	81.7M
Intangible Assets	145M	142M	3.3B	3.3B	3.0B	3.1B
Other Liab	202M	303M	915M	649M	746.4M	783.7M
Current Deferred Revenue	167M	186M	234M	245M	252M	264.6M
Other Assets	179M	609M	445M	212M	243.8M	133.6M
Long Term Debt	1.1B	673M	1.7B	1.5B	1.5B	769.5M
Inventory	359M	372M	431M	568M	587M	616.4M
Property Plant And Equipment Gross	1.4B	1.5B	1.7B	1.7B	2.7B	2.8B
Property Plant Equipment	889M	922M	1.7B	1.1B	1.3B	1.3B
Good Will	824M	897M	7.1B	3.2B	2.5B	2.7B
Treasury Stock	(2.6B)	(3.0B)	(3.8B)	(3.7B)	(3.3B)	(3.2B)
Net Tangible Assets	4.3B	4.3B	377M	4.1B	4.7B	4.9B
Retained Earnings Total Equity	4.1B	4.7B	5.5B	1.1B	1.3B	2.0B

Pair Trading with Illumina

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Illumina position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Illumina will appreciate offsetting losses from the drop in the long position's value.

Moving against Illumina Stock

0.69	VCNX	Vaccinex	Pair Corr
0.58	DTIL	Precision BioSciences	Pair Corr
0.53	VALN	Valneva SE ADR Downward Rally	Pair Corr
0.52	ME	23Andme Holding	Pair Corr
0.51	DRMA	Dermata Therapeutics	Pair Corr

The ability to find closely correlated positions to Illumina could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Illumina when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Illumina - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Illumina to buy it.

The correlation of Illumina is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Illumina moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Illumina moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Illumina can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Illumina offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Illumina's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Illumina Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Illumina Stock:

How To Invest In Illumina

Details

Is Illumina Stock a good investment?

Details

What is Illumina's Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.

You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Illumina. If investors know Illumina will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Illumina listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.96)

Earnings Share

(9.98)

Revenue Per Share

27.654

Quarterly Revenue Growth

(0.04)

Return On Assets

0.0262

The market value of Illumina is measured differently than its book value, which is the value of Illumina that is recorded on the company's balance sheet. Investors also form their own opinion of Illumina's value that differs from its market value or its book value, called intrinsic value, which is Illumina's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Illumina's market value can be influenced by many factors that don't directly affect Illumina's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Illumina's value and its price as these two are different measures arrived at by different means. Investors typically determine if Illumina is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Illumina's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Illumina Total Revenue vs Ebitda Analysis

Total Revenue vs Ebitda

Total Revenue vs Ebitda Correlation Analysis

Correlation Coefficient

Total Revenue

Ebitda

Illumina fundamental ratios Correlations

Illumina Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Illumina fundamental ratios Accounts

Pair Trading with Illumina

Moving against Illumina Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Current Deferred Revenue	+ 0.99	Net Receivables
Total Stockholder Equity	+ 0.98	Total Assets
Accounts Payable	+ 0.98	Total Assets
Total Liab	+ 0.98	Short Long Term Debt Total
Intangible Assets	+ 0.98	Other Stockholder Equity
Common Stock	+ 0.97	Common Stock Shares Outstanding

Other Stockholder Equity	- 0.63	Short Term Investments
Intangible Assets	- 0.62	Short Term Investments
Short Term Investments	- 0.45	Non Current Assets Total
Other Current Assets	- 0.42	Short Term Investments
Other Liab	- 0.41	Short Term Investments
Short Term Investments	- 0.41	Net Debt